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Abstract
Background: Transmissible spongiform encephalopathy describes a family of diseases affecting both man and
animals. Current tests for the diagnosis of these diseases are based on the detection of an abnormal misfolded
form of the host protein PrP which is found within the central nervous and lymphoreticular systems of affected
animals. Recently, concern that this marker may not be as reliable as previously thought, coupled with an
urgentneed for a pre-clinical live animal test, has led to the search for alternative assays for the detection of TSE
disease.
Methods: This "proof of concept" study, examines the use of differential protein expression profiling using
surface enhanced laser desorption and ionisationtime of flight mass spectrometry (SELDI-TOF) for the diagnosis
of TSE disease. Spectral output from all proteins selectively captured from individual murine brain homogenate
samples, are compared as "profiles" in groups of infected and non-infected animals. Differential protein expression
between groups is thus highlighted and statistically significant protein "peaks" used to construct a panel of disease
specific markers.
Studies at both terminal stages of disease and throughout the time course of disease have shown a disease specific
protein profile or "disease fingerprint" which could be used to distinguish between groups of TSE infected and
uninfected animals at an early time point of disease.
Results: Our results show many differentially expressed proteins in diseased and control animals, some at early
stages of disease. Three proteins identified by SELDI-TOF analysis were verified by immunohistochemistry in
brain tissue sections. We demonstrate that by combining the most statistically significant changes in expression,
a panel of markers can be constructed that can distinguish between TSE diseased and normal animals.
Conclusion: Differential protein expression profiling has the potential to be used for the detection of disease in
TSE infected animals. Having established that a "training set" of potential markers can be constructed, more work
would be required to further test the specificity and sensitivity of the assay in a "testing set". Based on these
promising results, further studies are being performed using blood samples from infected sheep to assess the
potential use of SELDI-TOF as a pre-mortem blood based diagnostic.
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Background
Transmissible spongiform encephalopathies (TSEs) are a
group of diseases affecting the central nervous and lym-
phoreticular system of both man (Creutzfeldt-Jakob dis-
ease (CJD))[1] and animals (e.g. bovine spongiform
encephalopathy (BSE)[2], scrapie in sheep [3] and
chronic wasting disease (CWD)[4] in deer). The diseases
typically have a long asymptomatic stage before a rapid
neurodegenerative stage leading to death. Definitive diag-
nosis has historically therefore, been restricted to post -
mortem examination of brain tissue for the presence of
pathological hallmarks of the disease such as spongiform
changes and the deposition of an abnormal disease
related form of the prion protein termed PrPd(ddenotes a
disease associated form of the host encoded protein PrPc)
[5]. Following an outbreak of BSE in cattle which was sub-
sequently linked to the emergence of a new human form
of the disease, vCJD, commercial testing for surveillance
purposes has focused on detection of this protein (PrPd)
in brain tissue homogenates. Most assays, such as immu-
noassay, utilise the distinct protease resistance property of
PrPd  by digesting samples with proteinase K, which
increases the specificity and sensitivity of PrPd detection.
These assay systems [6] are only reliable if PrPd always
associates with TSE infectivity, however several models of
disease have now been described in which transmission of
disease was achieved from tissue with little or no detecta-
ble PrPd [7-9]. In addition, atypical forms of sheep scrapie
have recently been described in Europe [10] which are not
conclusively identified by most of the current commer-
cially available diagnostic assay systems due to differences
in the degree or extent of PrPd resistance to proteinase K.
PrPd is also difficult to detect in blood, and following the
possible transmission of vCJD through the transfusion of
blood or blood products in humans[11,12], there is now
an urgency to seek new types of testing regimes which
could be applied at a pre-clinical stage of disease in both
man and animals. Several other candidate proteins have
been proposed to be markers of TSE disease [13] however
as single markers their reliability (with the exception of
PrPd)has remained unproven.
The emerging field of proteomic technology offers the
potential to discover new putative markers for diagnosis
in many diseases. Assays are currently being developed for
other diseases such as cancer [14,15], combining the
strengths of proteomics with powerful bioinformatics
tools, utilising multiple protein biomarkers in data driven
predictive assays. The benefits of high throughput auto-
mated analysis with the potential of high sensitivity and
specificity make this type of assay an attractive alternative
to single marker assays. In this study we investigate a pro-
teomic approach to establish a multi marker pattern rec-
ognition diagnostic assay using surface enhanced laser
desorption and ionisation time of flight spectrometry
(SELDI -TOF MS) and bioinformatics to identify differ-
ences in protein expression between TSE diseased and
non-infected murine brain tissue samples, and create a
mathematical model of disease (disease profile map). As
it is the combined profile or pattern of protein expression
differences which is applied as a mathematical algorithm,
the identity of each component protein is not required. In
contrast to other mass spectrometry approaches where the
complexity of the proteome is addressed by pre-fractiona-
tion processes, in this technology the crude sample is
applied directly to a specialised chromatographic surface
which selectively binds subsets of proteins according to
their biochemical properties.
Other proteomic and genetic human wide population
studies have highlighted the need to restrict variables in
sample sets, such as, genetic, gender, and age background,
in order to achieve interpretable results. TSE disease
research is further complicated by the long asymptomatic
incubation associated with disease. Taking these factors
into consideration we examined the feasibility of applying
this novel multi-marker approach to TSE diagnosis using
a well characterised experimental murine model of TSE
disease, initially using brain tissue in these studies as the
major pathology in TSE disease is confined almost with-
out exception to the CNS. The experimental model used
in these studies (CVF1 mouse model infected with an
experimental TSE strain (scrapie isolate ME7) [16,17] is a
highly reproducible model of TSE disease in an inbred
mouse line and has been used extensively in studies
within our laboratory. This model produces a severe and
defined pathology in the CA1 region of the hippocampus
providing the opportunity to study differential protein
expression in an area of the brain which has the highest
probability of discovering TSE disease specific differences.
The establishment of a SELDI directed diagnostic panel in
CNS could then be translated to large animal studies and
extended in accessible tissues such as blood with the aim
of developing a robust pre-mortem diagnostic.
Methods
Animals
All animal experiments were approved by the local Ethical
Review Committee and performed under licence to the
UK Home Office in accordance with the Animals (Scien-
tific Procedures) Act 1986.
In the terminal study a group(n = 12) of ~10 ten week old
male mice (F1 cross between C57Bl/Dk and VM/Dk
([18]) were intracerebrally injected (0.02 ml 1% (w/v))
with a brain suspension infected with ME7 scrapie isolate.
A control group (n = 12) ten week old mice were similarly
injected with a normal brain suspension. The time course
experiment was set up in the same way as above with two
groups of animals (n = 6NB n = 6ME7) which were seriallyBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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culled at thirty day intervals. Animals were monitored for
clinical signs of disease and on reaching the terminal stage
of disease were culled by cervical dislocation. Brain sam-
ples were flash frozen and stored at -70°C. Microdissec-
tion of the brain was carried out as described in Barr et al
(2004) [19].
Sample preparation
Brain tissue samples were homogenised in buffer (100
mM HEPES pH7, 100 mM NaCl, 0.05% CHAPS) placed
on ice for 30 minutes, centrifuged and the supernatant
removed (S1). The remaining pellet was re-suspended in
90 μl buffer (5 M guanidine-HCl, 50 mM Tris pH8, 0.5%
CHAPS) incubated on ice for 3 hours centrifuged and the
supernatant removed (S2). Total protein was estimated
using a Protein BCA kit (Pierce).
SELDI -TOF analysis
Two array types were used for analysis, a strong anionic
exchange surface (SAX/Q10), and a weak cationic
exchange surface (WCX/CM10). Arrays were prepared in a
bioprocessor by washing with appropriate buffer (CM10-
100 mM ammonium acetate pH4.5 Q10-100 mM Tris
pH8), and then 5 μg of each sample was applied to wells
containing 90 μl buffer and incubated for 40 minutes at
room temperature. After washing in buffer the arrays were
dried and two applications of 0.8 μl matrix solutions (sin-
napinic acid/50% acetonitrile/0.5% TFA) made to each
spot on the array.
Arrays were analyzed on a PBSII ProteinChip®  reader
(Ciphergen Biosystems, Feemont, CA.) using the accom-
panying software (ProteinChip® Version 3.2), two scans of
each sample optimized a range 3000-30,000 m/z and
25,000-100,000 m/z. Data was averaged over 300 tran-
sients on each spot and externally calibrated using a pro-
tein standard mixture (All-in-1 Protein Standard,
Ciphergen Biosystems). All data collected from individual
arrays used at the same settings were saved in a separate
experimental files e.g. WCX low laser S1, SAX high laser
S2. Data files were corrected by subtracting the back-
ground noise and normalized to the same total ion cur-
rent. Peak identification and clustering was achieved
using the Biomarker Wizard software (Ciphergen Biosys-
tems). Settings for cluster formation were first pass S/N 5
in 20% of all spectra and second pass S/N 2. Cluster mass
window was 0.3% of the mass. Single marker statistics
were calculated using the non-parametric Mann-Whitney
(U test) on the peak intensities.
Statistical analysis
The statistical package R  http://www.R-project.org was
used to carry out statistical analysis of the data. For each
supernatant/array type/laser combination the output
from the Biomarker Wizard software was read into R. A
two sample t-test was used to identify significant proteins
which were then examined pair wise using scatterplots.
The subset of significant proteins was used as an input to
cluster analysis and principal components analysis.
Protein purification and identification
Supernatants from infected (× 2) and uninfected (× 2)
brain tissue samples were fractionated on minispin col-
umns (Sigma-Aldrich) packed with 200 μl QHyperDF
resin (Biosepra). Columns were washed sequentially and
fractions eluted with 500 μl of buffers Tris-HCl pH9,
HEPES pH7, NaAcetate, pH4 and 5 NaCitrate pH3 and
finally an organic fraction with a solution of 33% isopro-
panol/0.1% TFA. Each fraction was spotted on a NP20
and CM10 array and analyzed on the ProteinChip® reader
to assess the presence of the protein peak of interest. The
fractions pH3 and "flow through" displaying the presence
of the peak of interest were further fractionated on a
hydrophobic column (Pierce Pepclean C18) by sequen-
tially washing with 10%, 40% and 70% acetonitrile/
0.1%TFA. Again these fractions were spotted on a NP20
array and analyzed on the ProteinChip® reader. The frac-
tions with displaying the presence of the peak of interest
were then run on an SDS-PAGE gel (Invitrogen NuPAGE
system using 12% Bis-Tris Nu-PAGE gel). The gel was
stained with Coomassie blue (R-250 Sigma-Aldrich). Two
standard protein ladders (See-blue, Multimark, Invitro-
gen) were used to indicate the approximate mass weight
of the bands and a bands at 10-12 kDa were excised by
punching with a small diameter needle (Harris punch,
Sigma-Aldrich) and placing in a micro centrifuge tube.
Samples were frozen and kept at 70°C.
In-gel digestion
The excised gel bands were treated to remove the Coomas-
sie stain and SDS by incubating successively with 200 μl
of 50% methanol/10% acetic acid for 30 minutes, 200 μl
of 50% acetonitrile/100 mM ammonium bicarbonate
(pH 8) for 30 minutes, and 100 μl acetonitrile for 10 min-
utes. The gel pieces were dried in a Speed-Vac. The dried
gel pieces were rehydrated with 20 μl of 50 mM ammo-
nium bicarbonate (pH8) containing 10 ng/μl modified
trypsin (Roche Applied Science) and incubated for 16
hours at 37°C.
Protein identification by peptide fragmentation using a
tandem mass spectrometer equipped with a PCI-1000
ProteinChip Interface Single MS and MS/MS spectra were
acquired on a tandem mass spectrometer equipped with a
Ciphergen PCI-1000 ProteinChip Interface. A 1 μl aliquot
of each protease digest was spotted on a NP20 Protein-
Chip Array. 1 μl of saturated CHCA in 50% ACN, 0.5%
TFA was immediately applied to the spot and the two
solutions were mixed by pipeting. Spectra were collected
from 800 Da to 3500 Da in single MS mode. After review-BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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ing the spectra, specific ions were selected for MS/MS anal-
ysis. The CID spectra were submitted to the database-
mining tool Mascot (Matrix Sciences) for identification of
Cpn10 and FKBP12 (See additional file 1: Hsp10 ID and
additional file 2: FKBP12 ID). For the identification of
DBI spectra were collected directly on a ProteinChip
Enterprise instrument and CID spectra submitted to Pro-
found http://prowl.rockefeller.edu/prowl-cgi/pro
found.exe (See additional file 3: DBI ID).
Immunocytochemistry and confocal microscopy
Coronally cut 6 μm paraffin embedded formol fixed brain
sections from terminal animals (~260 dpi) were de-
waxed, microwaved in citrate buffer quenched with
methyl peroxide and blocked using normal goat serum.
Sections were incubated for one hour with either the pri-
mary antibody (anti-Cpn10 rabbit polyclonal antibody,
Stressgen Bioreagents, (SP110) 1:400 dilution, anti-DBI/
ACBP rabbit polyclonal antibody, Santa Cruz Biotechnol-
ogies,1:200 dilution, anti- FKBP12 rabbit polyclonal
Affinity Bioreagents PA1026A 1:500, and anti-Cpn60
mouse monoclonal, Stressgen Bioreagents,(BAF2584).
Sections from animals inoculated with normal brain
homogenate and sacrificed at the same time as terminal
animals were similarly treated. Control sections to check
for background interference were incubated as the other
sections substituting the primary antibody with normal
rabbit or mouse serum. Sections were washed and a bioti-
nylated secondary antibody goat anti-rabbit for the poly-
clonal rabbit primaries or goat anti-mouse for mouse
primary (Jackson Laboratories) applied at 1:600 dilution
for one hour. Steptavidin was applied (Vector Labs. Inc.
Vectastain ABC kit) followed by DAB for 4 minutes and
counterstaining was achieved using heamatoxylin and
Tapps reagent. For confocal analysis of Cpn10 the first
steps of the protocol were followed then the fluorescent
secondary antibody (Alexa 488 goat anti-rabbit, Molecu-
lar Probes) was applied for one hour, washed and
mounted with fluorescent mounting medium (DAKO).
Imaging was achieved using a Zeiss LSMS PASCAL confo-
cal microscope with a FITC filter.
Results
A series of experiments were carried out to assess the capa-
bility of the SELDI approach in distinguishing pathologi-
cal changes both between different brain areas and
between TSE infected and non infected animals. A small
pilot study (no. = 2 infected, no. = 2 uninfected at termi-
nal stage of disease (260 dpi)) examined if any differences
between normal and diseased groups could be detected in
particular brain areas (hippocampus and cerebellum) of
the murine TSE model. The main studies focused on
results in brain tissue samples from animals (no = 12
infected, no = 12 uninfected) clinically assessed to be at
the terminal stage of disease (~260 days post injection)
and from animals (no. = 6 infected, no. = 6 uninfected)
culled at intervals of thirty days post injection (30, 60, 90,
120, 150, 180, 210, 240 and terminal) throughout the
course of infection. Trials with fewer samples were used to
establish standardised protocols. In all the experiments
samples of brain tissue were microdissected [19] from
areas of the brain (hippocampus and cerebellum) of
groups of age matched (~10 weeks old) animals injected
intracerebrally with either TSE (scrapie isolate, ME7)
infected or normal brain homogenate inocula. We
hypothesized that protein differences between normal
and scrapie infected animals would be more apparent in
the hippocampus where pathology is severe, compared
with the cerebellum where there is no obvious pathology
in this model. As described in the Methods section, super-
natant solutions of homogenized samples, S1 (soluble
proteins) and S2 (insoluble proteins) were spotted on two
array types, weak cationic (WCX/CM10 ProteinChip®
Array) and strong anionic (Q10/SAX ProteinChip® Array)
exchange surfaces. For each brain therefore there were
four samples, cerebellum S1, S2, hippocampus S1 and S2
on two different array surfaces which were designed to iso-
late different sub-groups of proteins from the proteome.
Protein expression differences are detected in a brain area 
known to exhibit TSE specific pathology
In the pilot study, spectra from the same brain area in
both the control and diseased groups displayed protein
expression profile similarities (Figure 1A) and differences
(Figure 1B). Expression within the same brain can be seen
in Figure 1C, with clear differences between the cerebel-
lum and the hippocampus. Differences between the
supernatant extracts were also apparent. This confirmed
that we had isolated different sub groups of proteins
which were reproducible between similar sample types.
Protein peaks found in all samples generated under the
same conditions e.g. all cerebellum S1 samples on WCX
array at a particular laser power, were then clustered
(Biomarker Wizard™) and the peak intensities of diseased
and control samples statistically compared (Mann-Wit-
ney). Clusters of statistically significant proteins at partic-
ular m/z ratios can be seen in Table 1. Using this method
only two biomarkers in the cerebellum were revealed
compared to thirty in the hippocampus, indicating that
the differences observed in protein expression reflected
the extent and severity of disease specific pathological
change. If the markers were indicative of differences unre-
lated to scrapie infection we would have expected to find
a more evenly distributed number of markers over both
brain areas.
Differential protein expression profiling is reproducible
Having established differential protein expression
between normal and diseased groups in the pilot study we
then proceeded to extend the sample group numbers withBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Differential protein expression profiling spectra displayed by ProteinChip software Figure 1
Differential protein expression profiling spectra displayed by ProteinChip software. Spectra of proteins expressed 
in scrapie infected (n = 2) and control (n = 2) brain homogenates from animals at the terminal stage of disease (~260 dpi) (A) 
displaying similar spectral peaks in all samples. (B) spectra as in (A) at a different part of the spectrum displaying differential 
expression at a lower molecular weight. (C) differential expression shown in different areas of the same brain.BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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the aim of consolidating the results. This type of assay
relies on a high degree of reproducibility to achieve robust
data for the incorporation into the final disease profile
therefore we focused on developing a robust protocol
which could be used throughout the course of the study.
For this a series of optimisation experiments were per-
formed on brain tissue samples (no. = 4 ME7 terminal 4
NB). The effect of pH (Figure 2A) and concentration (Fig-
ure 2B) were examined. Samples were incubated and
arrays washed with a range of buffers at different pH
(WCX/CM10 pH4-7, SAX/Q10 pH6-9). The optimal sam-
ple concentration was examined with a range of dilutions
(undiluted, 1:5, 10, 20, 30, 40) of samples of a known
total protein concentration. We devised a scoring system
to visually assess the quality of the peaks, for example, res-
olution of peaks, height of intensity and quality of base-
line (See additional file 4: Optimising experiments, for an
example of scoring system). In conclusion, 5 μg total pro-
tein was determined as optimal for application to the
array using a pH of 4.5 for the WCX/CM10 array and pH8
for the SAX/Q10 array (see Methods). As in the pilot
study, there were very few clusters found in the cerebellum
which were significantly different between diseased and
normal groups therefore we concentrated on the hippoc-
ampus samples. Variation in peak intensity was deter-
mined by examining at least ten peaks in several samples
and a coefficient of variation of 7 - 26% on the WCX and
9 - 36% on the SAX arrays was achieved. Laser power was
also examined. This allows better resolution of peaks in
the lower molecular mass range (2 kDa - 30 kDa) and the
higher molecular range (30 kDa -100 kDa). In the termi-
nal study two laser settings are displayed in the results
(low and high). The data from one laser setting was used
in the time course study for statistical analysis. An exam-
ple of the effect of laser settings can be seen in Additional
file 4: Optimising experiments, aliquots sheet, where one
brain sample which was prepared using the protocol
described in "Methods" and aliquoted into several tubes
was spotted on each spot of two Q10 arrays. Three laser
settings were applied and covariance analysis applied. The
average values were similar in the lower (CV = 22%) and
mid laser (CV = 20%) strengths but reach an unacceptably
high value (CV = 300%) at the extreme high laser strength.
A schematic diagram of the final protocol can be seen in
Figure 2C.
During the course of this study the SELDI technology
evolved rapidly resulting in better array surface and instru-
ment technology becoming available with older instru-
ments becoming obsolete. For this reason the time course
study was carried out separately from the terminal study
on a different instrument with modified arrays. Despite
this we found protein markers identified in the terminal
study (Table 2) also appearing in the time course study
(Tables 3, 4, 5 and 6). The difference in daltons between
the clusters found in the terminal study and the time
course study is shown comprehensively in Table 7. Never-
theless there was found to be a close correlation between
the results obtained using different machines in different
laboratories and at different times. The variability within
individual animals should also be considered, the termi-
nal study running several months before the time course
study. Several proteins of the same mass were found at
many time intervals throughout the course of disease
some at early stages of disease (see Tables 3, 4, 5 and 6),
adding to confidence that the system is reliable and is
reproducible.
SELDI analysis produces numerous 'clusters' common to 
both TSE infected and normal animals
In the study of the terminal brains, spectra were generated
from the two fractions (S1-soluble and S2-insoluble) in
each of the TSE and uninfected brain samples. Each spot
on the arrays in the terminal study was also subjected to
two laser conditions (high laser and low laser). This gen-
erated 48 spectra for each 'set' i.e. S1 low, S1 high laser, S2
low and high laser on the two array surfaces (WCX and
SAX). The spectral data was analyzed, by clustering peaks
of similar mass (m/z ratio >2000) common to all the sam-
ples followed by statistically analyzing (Mann-Whitney
(U test)) the peak intensities between normal and disease
groups (See additional file 4: Optimising experiments,
Biomarker Wizard sheet for an example). A total of 159
clusters were identified on the WCX array and 165 clusters
on the SAX array. Protein peaks from individual samples
displaying high statistical significance can be seen as an
Table 1: Comparison of brain areas in scrapie infected murine model
Brain Area Potential scrapie biomarkers
SAX array WCX Array
Cerebellum
Supernatant S1 none none
Supernatant S2 4.9, 5.4 kDa none
Hippocampus
Supernatant S1 4.2, 4.6, 5.2, 7.4, 7.8, 22.3, 28, 29 kDa 5.1, 5.4, 6.2, 6.7, 7.1, 7.5, 9.9, 20.8, 35.1, 77 kDa
Supernatant S2 5.7, 6.9, 11.3, 16.8, 20.2, 20.9, 22.0, 22.7 kDa 4.8, 6.0, 11.9, 13.4, 14.2, 24.0 kDaBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Optimisation Figure 2
Optimisation. (A) Effect of pH. Supernatant 1 and supernatant 2 fractions were applied to arrays and buffers of various pH 
used for incubating samples and washing of arrays. (B) Effect of dilution. Same sample diluted and applied to array (further 
explored in Additional File 4: optimising experiments). (C) Established protocol for the preparation of samples, handling and 
analysis of data.BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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overlay in spectral format in Figure 3A. A full list of clus-
ters which displayed statistically significant differences
between normal and diseased groups can be viewed in
Table 2.
Statistical analysis reveals many statistically significant 
proteins differentially expressed between diseased and 
normal groups
The data files were also extensively tested using the statis-
tical package R (see Methods) and were examined by clus-
ter analysis (Figure 3B) and pair wise using scatterplots
(Figure 3C).
Results show many statistically significant peaks, 68 with
p-value < 0.005 and 25 with p-value of < 0.01 across the
two array surfaces (Table 2) separating samples into two
distinct groups, TSE infected (ME7) and normal unin-
fected (NB). Increased statistical power was achieved by
partnering six of the most highly significant protein peak
intensities at masses (m/z) 7063, 7847, 8811, 10101,
10300 and 12449 (WCX array surface) showing total sep-
aration of the groups (see Figure 3A, B and 3C). This panel
of markers represents the basis of a diagnostic test using
pattern recognition as a 'fingerprint' for the diagnosis of
scrapie. Using intensity level thresholds a decision tree
algorithm can be constructed as in Figure 4 to distinguish
between normal and diseased samples. The full data anal-
ysis detailing the mass to charge ratios of each significant
peak can be viewed in the supplementary files (See addi-
tional file 5: Full statistical analysis of terminal study).
Temporal protein differential expression profiles are also 
statistically significant
Having established that differential protein profiling was
possible at the terminal stage of disease we were interested
to establish if this approach could also be applied to the
earlier pre-clinical stages of TSE disease. Brain samples
were collected from animals at thirty day intervals and
processed as in the terminal study. The resultant data from
the analysis of the individual time points was statistically
tested as before thus producing statistic reports for each of
the eight time points. An extensive coverage of the statisti-
cal analysis can be viewed in the additional files (See addi-
tional files 6: full statistical analysis of CM10 S1,
additional file 7: full statistical analysis of Q10 S1, addi-
tional file 8: full statistical analysis of CM10 S2 and addi-
tional file 9: full statistical analysis of Q10 S2). The data
files were separately analysed by "Ciphergen Express®"
software which was used to examine the relationship
between individual peaks over the time course of disease.
In summary, many differential protein expression profile
differences were found to be statistically significant as
shown in Tables 3, 4, 5 and 6. Proteins were found to be
up or down-regulated during the course of disease as
would be expected (for example, see Figures 5, 6). Some
statistically significant markers were also found at early
Table 2: Terminal Study - List of protein peaks (m/z)
Array type
S1 WCX S2 WCX S1 SAX S2 SAX
p = 0.000005 p = <0.005 p = <0.01 p = <0.01
m/z m/z m/z m/z m/z m/z
4807 ↓ 9270 ↓ 29186 ↓ 6026 ↑ 6311 ↑ 10911 ↑
5242 ↓ 10101 ↑ 31074 ↓ 7621 ↑ 9102 ↑ 18482 ↓
5289↓ 10300 ↑ 31590 ↑ 7834 ↓ 10183 ↑ 22260 ↓
5303 ↓ 10438 ↑ 31769 ↑ 8280 ↑ 10341 ↑ 25108 ↓
5471 ↓ 10834 ↑ 34529 ↑ 8371 ↓ 10403 ↑ 28176 ↓
5780 ↓ 11314 ↑ 39288 ↓ 8808 ↓ 10535 ↑ 39393 ↑
5873 ↓ 11926 ↓ 39656 ↓ 8878 ↑ 10627 ↑ 44659 ↑
6120 ↓ 12240 ↓ 39112 ↓ 9183 ↓ 10786 ↑ 50452 ↑
6456 ↓ 12317 ↓ 42708 ↓ 9989 ↑ 10902 ↑ 67092 ↑
6558 ↓ 12449 ↓ 43020 ↓ 10097 ↑ 12302 ↑ 97601 ↑
6673 ↓ 12523 ↓ 56090 ↑ 10996 ↓ 14694 ↑
7063 ↓ 13594 ↑ 58596 ↓ 18492 ↓ 21276 ↑
7184 ↑ 13876 ↓ 21043 ↓ 28175 ↓
7550 ↑ 14187 ↓ 33122 ↓ 57798 ↓
7847 ↓ 15826 ↑ 39115 ↓ 66480 ↑
8207 ↓ 17840 ↓ 39353 ↓
8375 ↓ 22067 ↓ 47205 ↓
8811 ↓ 22431 ↓ 53790 ↑
9011 ↓ 28691 ↓ 66509 ↑
p value -- the cut off value at which proteins are significant
Diseased samples significantly ↓ down regulated ↑ up regulated.
Figures in bold denote peaks which completely separate the groupsBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Panel of biomarkers Figure 3
Panel of biomarkers. (A) data from the ProteinChip® Reader is visualized in spectral format as clusters of differentially 
expressed protein peaks at 7063 (cluster X21), 7847(X26), 8811 (X31), 10101 (X34), 10300 (X35), 12449 (X43) m/z. Each 
peak within a cluster represents an individual brain sample i.e. 12 scrapie infected (red) and 12 uninfected (green) animals. Cor-
responding box plots for each marker displays the separation of markers based on peak height intensity, scrapie infected (red) 
uninfected (green). (B) cluster analysis shows separation of groups, scrapie infected (ME7) and uninfected (NB) samples. (C) 
pairwise plots of the above six highly significant proteins one protein against the other (red indicates scrapie infected green 
indicates control).BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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stages of disease (30-90 days post injection) and many
well before clinical signs were apparent (240 days post
injection). Differential expression between diseased and
normal samples over both array types (Q10 and CM10)
and supernatant fractions was found to be statistically sig-
nificant. Six proteins captured on the Q10 array from
supernatant 1 were significant (p <= 0.05) at 30 days post
injection. Total separation of groups was achieved at 90
days post injection on both the Q10 (12 proteins p <=
0.01 Figure 5) and CM10 arrays (2 proteins p <= 0.05).
Eight proteins clustered together, on the CM10 array, sep-
arated the groups at 210 dpi (Figure 6). As in the terminal
study a cluster at 10180 Da (CM10) was found to separate
the groups at 210 days post injection (p <= 0.01) and at
End Point (p <= 0.01) (see Figure 6). A cluster at 22300 m/
z displayed significant differential expression in both
supernatant fractions on the CM10 array (Figure 6). A
receiver operation characteristic (ROC) analysis, which is
a measure the sensitivity and specificity of a marker, was
applied to a few markers with encouraging results. Clus-
ters at 16885 (p = 0.00194), 5235(p = 0.0019) (Figure 5),
8445(p = 0.0095) and 6333(p = 0.0094) m/z gave values
of 1 indicating that these would be ideal candidates for
inclusion in a panel of markers, distinguishing between
diseased and normal groups at an early stage of disease
(90 dpi). Several proteins displayed the same expression
difference (up-regulated or down regulated) in most of
the time points for example peaks on the Q10 array at
5334 m/z displayed up regulation in diseased tissue at
90,120, 210, 240 and EP whilst 13642 and 14183 m/z dis-
played down regulation at the same time points.
A column at the end of each table numbered 3, 4, 5 and 6
compares the mass of significant markers found in the ter-
minal study with the time course study. A comprehensive
list comparing common peaks found in the terminal
study with the temporal study is found in Table 7.
SELDI Directed Protein Identification
SELDI technology can be used, in addition to profiling,
for the identification of individual proteins by targeting a
protein of interest for isolation and purification. Whilst
for the purposes of this study, the identification of each
individual protein contributing to the final mathematical
model was not necessary; we were interested to explore
the possibility of identifying differentially expressed pro-
teins from the murine brain tissue samples which may be
important in disease mechanisms. Protein peaks shown to
be statistically significant were detected in the range of
~10-12 kDa. The conditions with which the proteins were
visualised i.e. a weak cationic exchange array washed with
ammonium acetate pH 4.5, directed the fractionation
process (see Methods). Each fraction generated was
applied to the CM10 array and examined for the presence
of the desired peak. Fractions containing the peaks were
then further purified by 1D SDS-PAGE gel electrophoresis.
The candidate proteins were excised from gels and pre-
pared for identification by peptide mass fingerprinting
using a tandem mass spectrometer equipped with a Pro-
teinChip® interface. A peak profile with a mean m/z of
10825 (Figure 7A) displaying up-regulation in the dis-
eased samples was identified as Hsp/Cpn10 Mascot score
41. Further peaks at 10 (Figure 7B) and 11 kDa (Figure
7C) were also isolated and identified by the same meth-
ods. The 10 kDa up-regulated peak was identified by tan-
dem mass spectrometry as diazepam binding inhibitory
protein (DBI also known as Acyl Co A binding protein
(ACBP) (minimum sequence coverage 48%) and a down-
regulated peak at 11 kDa was identified as FK506 binding
protein 12 (FKBP12, mascot score 53). The gene for
FKBP12 was shown to be up-regulated in a similar murine
scrapie model by Brown et al [20]. In a recent systems
approach study, DBI gene expression was found to be up
- regulated in TSE disease [21] which would be in agree-
ment with our results. The yeast protein homologue to
mammalian Cpn10, GroES, has been shown to inhibit
GroEL in the conversion of PrPc to PrPSc[22].
Decision tree Figure 4
Decision tree. The intensity thresholds of two markers 
8811 Da and 10101 Da from the panel of markers in Figure 3 
were applied to mixed group data. Used in partnership these 
successfully identified the diseased group.BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Identified proteins localised by immunohistochemistry
We were also interested if the observed protein expression
differences seen in the SELDI spectra could be validated by
immunohistochemistry. In contrast to western blotting
which detects the total protein concentration of interest in
samples, immunohistochemistry is more applicable for
detecting subtle changes in the concentration and distri-
bution of proteins at a cellular level.
In Figure 7A, Hsp/Cpn10 staining is visible in the pyram-
idal cell layer of the CA3 region of the hippocampus. Sim-
ilar staining was apparent in the retrosplenial cortex and
giant cells in the dorsal raphe region of the medulla. In the
normal animals immunoreactivity was contained to small
discrete regions near the cell surface in contrast to the dis-
eased animals where several cells with heavily punctuate,
perineuronal staining was apparent. DBI/ACBP (Figure
7B) immunoreactivity was strongly detected in the dis-
eased animals with an up-regulation in the cytoplasm of
glial like cells.
FKBP12 staining was very diffuse and widespread in both
normal and diseased brain sections. Less staining was
apparent in the diseased brains (Figure 7C).
Table 3: Table of protein peaks (m/z) Q10 array Supernatant 1
DPI 30 60 90 120 180 210 240 EP Terminal study
P value <0.05 <0.05 <0.01 <1.00E-04 <0.05 <0.001 <0.001 <1.00E-04
m/z
2400 ↑
3243 ↑
5020 ↑
5234 ↑s ↑s ↑s ↑s ↑s
5469 ↓
6054 ↓s ↓s
6272 ↑s6 3 1 1 ↑
7670 ↓s ↓
7800 ↑↓
8445 ↓s ↓s ↓s
10085 ↑s ↑s1 0 1 8 3 ↑
10483 ↑s ↑s1 0 4 0 3   ↑
10707 ↑s ↑s ↑s1 0 7 8 6   ↑
12246 ↑↓
13037 ↑
13642 ↓s ↓s ↓s ↓s ↓s
14183 ↓s ↓s ↓s ↓s ↓s
14620 ↓↓ s ↓s ↓
14863 ↑s ↑s
15234 ↓s ↓
15333 ↓s
15460 ↓s ↓s
16885 ↓s ↓s ↓s ↓s
17090 ↓s ↓s ↓↓ s
17327 ↓s ↓s
18759 ↓
22292 ↓s ↓s ↓s ↓s
22484 ↓
26207 ↓s ↓s
28099 ↓s ↓s
28226 ↓s ↓s2 8 1 7 5   ↓
28898 ↓s ↓↓
35510 ↑
42483 ↓
57359 ↓s
59642 ↓
64051 ↓
84779 ↓s
DPI -- days post injection
p value -- the cut off value at which proteins are significant diseased samples significantly ↓ down regulated ↑ up regulated
S - significance completely separates groupsBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Discussion
Diagnosis of TSE infection in animals is currently only
achieved by the identification of PrPd in post-mortem or
biopsy tissue samples usually of brain. Efforts to produce
a robust ante mortem diagnostic which could be applied
to crude body fluids such as urine or blood has yet to pro-
duce a commercial assay. This may be due to the reliance
on identification of PrPd in these samples as the nature of
the infectious agent or isoform of infectious PrP in blood
is currently unknown. Indeed several models now exist of
disease transmission in the presence of low or undetecta-
ble levels of PrPd. Whilst several other protein markers
have been shown to up or down regulate during TSE dis-
ease, none individually have provided adequate specifi-
city and sensitivity for disease. The novelty of the SELDI
approach is the grouping together of several individual
biomarkers, displaying statistically significant differential
expression, in a data driven, decision tree algorithm which
is specific for the detection of TSE infection. Hence it is
not the power of an individual marker but the combina-
Table 4: Table of protein peaks (m/z) Q10 array Supernatant 2
DPI 30 60 90 150 180 210 240 EP Terminal study
p value <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.01 <0.001
m/z
3643 ↑
5790 ↑
5485 ↓
6740 ↓
7354 ↓s
8436 ↑↓ s
8543 ↓s
9376 ↓↓ ↓
9677 ↓ ↓
10712 ↑s ↑↑
11145 ↓
11264 ↑
11374 ↓↓
12246 ↑
14199 ↓
14625 ↓↓ s
16880 ↑
17084 ↑↓↓ s
18507 ↓ 18492↓
22297 ↓s2 2 2 6 0   ↓
22496 ↓s ↓
25072 ↓s2 5 1 0 8   ↓
25007 ↑
28325 ↓
30887 ↓
33748 ↑↑ s
39479 ↓
42895 ↑
44721 ↑s4 4 6 5 9   ↑
45959 ↑s
50631 ↑
50458 ↑s ↑s5 0 4 5 2   ↑
66563 ↑↑
66930 ↓
67150 ↑s6 7 0 9 2   ↑
88134 ↑
89273 ↑s
98034 ↑s
98318 ↑
97076 ↑s
96118 ↑s
101150 ↑s
DPI -- days post injection
p value -- the cut off value at which proteins are significant diseased samples significantly ↓ down regulated ↑ up regulated
S - significance completely separates groupsBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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tion of several differentially expressed markers into a TSE
specific profile that is diagnostic.
To establish the validity of using this technology and the
possibility of a data driven diagnostic assay for the detec-
tion of TSE disease, we decided to base this study on CNS
tissue with a view to extending to blood in the longer
term. The TSE's are primarily a disease of the nervous sys-
tem and there is much published evidence of temporal
pathological events where one would expect changes in
protein expression, for example, in the murine model
described in this study, changes in the synapses and in the
dendrites are present at an early stage of disease
[18,23,24]. Protein expression differences identified using
the SELDI-TOF technology, although not definitive, may
be indicative of these pathological changes. There is no
such published data on the pathogenesis of TSE disease in
blood. Low levels of the prion protein in blood coupled
with difficulty in detection due to the inability to distin-
guish the abnormal disease form PrPd in a background of
normal PrPc have hindered the application of a blood
based pre-mortem assay using PrPd as a marker. In this
study we sought to determine if the SELDI approach
would both distinguish diseased animals from uninfected
animals and determine the earliest time point at which
this is possible. By building confidence in the SELDI
approach using the CNS material we would be better
equipped to interpret results from any subsequent experi-
ments in body fluids such as blood.
We have established in this study that there are many
potential biomarkers which could be used together as a
panel for the construction of a decision tree classifier
which could be used to identify the presence of TSE dis-
ease. In addition we have confirmed the differential
expression of three proteins identified by SELDI using
immunohistochemistry.
The results of our initial experiments comparing an area of
the brain with no obvious pathology (cerebellum), with
an area displaying severe pathology in the same animal
(hippocampus) supported our hypothesis that the
Table 5: Table of protein peaks (m/z) CM10 array Supernatant 1
DPI 60 90 180 210 240 EP Terminal study
P value <0.05 <0.05 <0.01 <0.05 <0.01
m/z
4817 ↑↓ 4807 ↓
6333 ↑s
6435 ↓ 6456 ↓
6756 ↓
7599 ↑ 7550 ↑
8595 ↑
9405 ↓s
10180 ↑s ↑s1 0 1 0 1   ↑
13912 ↓s1 3 8 7 6   ↓
12426 ↓
15094 ↓
15730 ↓↑ s
17991 ↓↓ ↓
18579 ↓
19956 ↑s
21102 ↓
22322 ↓↓ s ↓↓ s
24920 ↑↑
24848 ↑s
26014 ↑
28780 ↓↓ 28691 ↓
28960 ↓
34200 ↑s
39492 ↓
42436 ↑
42509 ↑
152289 ↑
184754 ↑s
187228 ↑
p value -- the cut off value at which proteins are significant
↓ diseased samples significantly down regulated ↑ up regulated
S - significance completely separates groupsBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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number of differential protein expression differences cor-
related with the observed pathological changes already
documented in this murine model. At this terminal stage
of disease there are arguably many events which occur that
are not specific responses to TSE disease, but rather to the
more general responses to injection and disease in the
brain. However if this was a general effect we would have
also expected more expression differences in the cerebel-
lum. Building on these results, stringent quality control-
led protocols were developed to address reproducibility
by optimising sample preparation, instrument conditions
and data management.
The terminal study consolidated the initial results in a
larger group of samples with many differential expression
differences apparent. This experiment represented the
most extreme comparisons, infected versus non-infected
at the end stage of disease, therefore it was necessary to
examine time points during disease progression to ascer-
tain subtle changes occurring throughout the course of
disease which would indicate potential biomarkers for a
pre-clinical diagnostic panel. In this temporal study there
were numerous proteins in both uninfected and infected
groups which clustered together over a wide molecular
weight range and over several time points. Statistically sig-
nificant differentially expressed proteins grouped together
separated the scrapie brain homogenate inoculated group
from the normal brain homogenate inoculated group at
several time points however statistical significance for the
proteins individually was not achieved at every time point
throughout the course of disease. Further investigation of
the data (Tables 3, 4, 5 and 6) was carried out in the
Ciphergen Express software to ascertain if these protein
clusters observed as statistically significant at particular
time points were present at all time points. This analysis
shows a clear relationship between time points as demon-
strated in Figures 5 &6, with trends of up regulation or
down regulation apparent over the course of infection.
Given that these data are derived from individual animals
and the samples analysed in "batches" of samples over
time the results in expression differences are extremely
consistent. Several proteins displayed consistent up or
down regulation as displayed by the peak seen in Figure 7
at 10180 m/z which is particularly striking as the normal
group remains consistently low at all the time points
whereas the diseased group displays an up regulated trend
from an early time point. Utilizing similarly robust
biomarkers and combining highly significant markers at
specific time points, a diagnostic panel could be compiled
to be applied as a diagnostic decision tree algorithm for
the presence of TSE disease.
As previously stated in this study our primary aim was to
establish a data driven approach to diagnosing the pres-
ence of TSE disease at a pre-clinical time point. Although
there is no necessity to establish the identity of each pro-
tein for successful application of the diagnostic panel as a
data driven assay, we identified three differentially
expressed proteins (Cpn10, FKBP12, DBI) using data
from the SELDI analysis to support the strength of this
approach. Immunohistochemistry results confirmed the
differential expression observed in the SELDI data for all
three proteins identified. DBI was first isolated from brain
material[25] and is found in glial cells. As this scrapie
model displays extensive gliosis in the hippocampus it is
perhaps not surprising that the immunohistochemistry
results show increased staining in glial-like cells within
the scrapie brain. This gives us confidence that we are
Table 6: Table of protein peaks (m/z) CM10 array Supernatant 2
DPI 30 90 180 210 240 EP Terminal
P value <0.05 <0.05 <0.05 <0.01 <0.01 <0.01
m/z
3376 ↑
4116 ↑s
5706 ↓s ↓
5749 ↓
7615 ↓ 7621↑
7856 ↓ 7834↓
8154 ↓
8437 ↓
9023 ↓s ↓s
9683 ↓s
9973 ↑s ↑s9 9 8 9 ↑
9862 ↑
10325 ↑s ↑s ↓s
10799 ↓
11386 ↑s
12508 ↓↓ ↓ s
17096 ↓s
17266 ↓↓
18505 ↑↓ 18492↓
19988 ↓
21027 ↓s 21043↓
22172 ↓
22303 ↓s
24879 ↑
25129 ↑s
28118 ↑
28163 ↓
32517 ↓
32813 ↑
34052 ↑s
36515 ↑
39522 ↓↓
42278 ↑↓
50556 ↑s
51238 ↑
56855 ↓
66211 ↑s
83532 ↑
107215 ↑s
p value -- the cut off value at which proteins are significant
↓ diseased samples significantly down regulated ↑ up regulated
S - significance completely separates groupsBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Q10 array statistics Figure 5
Q10 array statistics. Panels show box plots of proteins found to be significantly different and separate groups at 90 days post 
injection(dpi) and 210(dpi). A cluster analysis of the proteins at 210 dpi displays separation of groups. Examples of protein 
marker differences over time (S1 16885 m/z, S1 14183 m/z, S1 5234 m/z) with corresponding ROC plots(5234,16885 m/z) 
showing diagnostic potential.BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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CM10 array statistics Figure 6
CM10 array statistics. Panels show a dot plot of statistically significant protein peaks at 210 days post injection, a cluster 
analysis of the same proteins displaying separation between groups. Protein markers at 10180, 22300 m/z supernatant 1 frac-
tion, and 14090 m/z supernatant 2 fraction plotted over time course of disease. 22300 m/z supernatant 2 fractions and 6333 m/
z supernatant 1 fraction separation of groups.BMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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Protein identification Figure 7
Protein identification. (A-C) data from the ProteinChip® Reader is visualized in spectral format as a cluster of peaks (indi-
vidual animals n = 12 normal and n = 12 scrapie infected) at 10834, 10101, 11784 m/z. Immunocytochemistry brain sections 
from terminally ill animals:-infected animals, (A-C ME7) and uninfected animals (A-C NB). (A) Cpn10, CA3 region of hippocam-
pus × 60 oil magnification cropped confocal Z series ME7 (upper panel), NB (lower panel).(B) DBI staining in the hippocampus 
and dentate gyrus of scrapie infected animal × 20 magnification(ME7 upper panel), NB(lower panel). (C) FKBP12 CA3 hippoc-
ampus ME7 (upper panel) and NB (lower panel) ×100 oil magnification.
NB
ME7 ME7
10700 10800 10900 11000
11700 11800 11900 12000 121
10000 10100 10200 10300
A B C
ME7
100 μm
NB
100 μm
50μm
NB
50μm
Table 7: Comparison Terminal study v Time course study
S1 WCX S2 WCX S1 SAX S2 SAX
TT C % TT C % TT C % TT C %
m/z m/z m/z m/z m/z m/z m/z m/z
4807 4817 0.2 7621 7615 0.08 6311 6272 0.62 18492 18507 0.08
6456 6435 0.3 7834 7856 0.28 10183 10085 0.97 22260 22297 0.17
7550 7599 0.6 18492 18505 0.07 10403 10483 0.76 25108 25072 0.14
10101 10180 0.8 21043 21027 0.08 10786 10707 0.74 44659 44721 0.14
13876 13912 0.3 9989 9973 0.16 28175 28226 0.18 50452 50458 0.01
28691 28780 0.3 67092 67150 0.09
T - terminal study, TC -- time course studyBMC Infectious Diseases 2009, 9:188 http://www.biomedcentral.com/1471-2334/9/188
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indeed isolating disease specific differentially expressed
proteins from the brain homogenates. Further investiga-
tion of possible roles in the pathogenesis of TSE disease
for these proteins will be required.
Conclusion
The project aimed to establish if this approach was feasi-
ble starting with tissue samples from the CNS which
would be the basis of a post-mortem test, still a surveil-
lance requirement for conclusive evidence of disease sta-
tus. We have targeted known areas where disease
associated changes occur in the murine scrapie model and
successfully demonstrated that a training set, based on
discriminating protein peaks can be obtained to form a
pattern based algorithm for the detection of TSE disease in
unknown samples. Having established that the technique
is valid based on these studies in CNS tissue, our ongoing
studies are being performed using a large archive of blood
samples from an ovine time course TSE infection study.
The training set of samples will be used to establish a pro-
tein fingerprint for TSE infection in blood, which will then
be tested against a testing set of samples (including blood
from sheep with other neurological diseases) to assess the
sensitivity and specificity of the assay. Markers will be
compared with those identified in the mouse studies to
determine whether any common patterns of differential
protein expression in TSE disease exist across different
species.
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